Innovations in Percutaneous Transluminal Coronary Angioplasty and Transcatheter Aortic Valves

This report covers innovations across the percutaneous transluminal coronary angioplasty and transcatheter aortic valve spaces. Innovations in both devices and techniques are reviewed. Devices covered include drug eluting stents, drug coated balloons, embolic protection devices and trascatheter valves. The report also examines the regulatory status of products under investigation.

Features and benefits

• Assess the markets for percutaneous transluminal coronary angioplasty devices and transcatheter valves.
• Forecast epidemiology of key cardiology indications which impact the PTCA and transcatheter aortic valve markets.
• Evaluate innovations in percutaneous transluminal coronary angioplasty devices.
• Analyze how percutaneous transluminal coronary angioplasty techniques are changing.
• Gain an understanding of the leading transcatheter aortic valves which are under investigation for approval.

Highlights

The global market for percutaneous transluminal angioplasty is valued at $9.1bn in 2010, and is set to grow at a CAGR of 13.8% to reach $19.1bn in 2016. The market is being driven by the rise in procedural volumes with an increase in the average age of the population in the US and Japan, and the increase in the penetration of PCI in Asia.

Future directions in the DES space focus on inventing DES that are safer (lower risk of thrombosis), more maneuverable in order to treat dispersed lesions, and have novel therapeutic properties, such as self-expandable DES, bifurcation stents and DES with more than one drug offering.

New imaging techniques are the main area of innovation in transcatheter aortic valves. Edwards Lifesciences Sapien valve became the first product to be approved in the US.

Detailed Table of Contents, Request Sample and more for the report: Innovations in Percutaneous Transluminal Coronary Angioplasty and Transcatheter Aortic Valves